Tectonic Therapeutic (TECX) Expected to Post Quarterly Earnings on Thursday

Tectonic Therapeutic (NASDAQ:TECX) will likely be issuing its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect Tectonic Therapeutic to announce earnings of ($1.3488) per share for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:00 PM ET.

Tectonic Therapeutic (NASDAQ:TECX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.16) by ($0.18). On average, analysts expect Tectonic Therapeutic to post $-5 EPS for the current fiscal year and $-6 EPS for the next fiscal year.

Tectonic Therapeutic Price Performance

Shares of NASDAQ:TECX opened at $27.92 on Tuesday. The business’s fifty day moving average price is $31.27 and its two-hundred day moving average price is $28.26. Tectonic Therapeutic has a fifty-two week low of $14.39 and a fifty-two week high of $39.53. The stock has a market capitalization of $526.85 million, a price-to-earnings ratio of -6.26 and a beta of 3.28.

Institutional Trading of Tectonic Therapeutic

Large investors have recently made changes to their positions in the business. Vestal Point Capital LP bought a new position in shares of Tectonic Therapeutic in the fourth quarter valued at about $6,842,000. Virtus Investment Advisers LLC grew its holdings in Tectonic Therapeutic by 165.5% during the 4th quarter. Virtus Investment Advisers LLC now owns 13,462 shares of the company’s stock worth $281,000 after acquiring an additional 8,391 shares during the last quarter. Orbimed Advisors LLC bought a new stake in Tectonic Therapeutic during the 4th quarter worth about $11,986,000. Opaleye Management Inc. acquired a new stake in Tectonic Therapeutic in the 4th quarter valued at about $4,480,000. Finally, Millennium Management LLC increased its position in Tectonic Therapeutic by 26.3% in the 4th quarter. Millennium Management LLC now owns 300,820 shares of the company’s stock valued at $6,275,000 after acquiring an additional 62,650 shares in the last quarter. Institutional investors own 62.63% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Raymond James Financial upgraded shares of Tectonic Therapeutic from an “outperform” rating to a “strong-buy” rating and boosted their target price for the company from $76.00 to $81.00 in a research note on Tuesday, May 26th. Zacks Research cut shares of Tectonic Therapeutic from a “hold” rating to a “strong sell” rating in a research report on Monday, July 20th. Wall Street Zen cut shares of Tectonic Therapeutic from a “sell” rating to a “strong sell” rating in a research report on Saturday, April 18th. Stifel Nicolaus assumed coverage on shares of Tectonic Therapeutic in a report on Monday, April 13th. They set a “buy” rating and a $75.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Tectonic Therapeutic in a research report on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $79.40.

Tectonic Therapeutic Company Profile

Tectonic Therapeutic, Inc engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.